Featured Employer
Alliance Imaging, Inc.
 High Quality Clinical CareThe nation's leading provider of diagnostic medical imaging services with 25 years of industry experience is seeking qualified professionals to join their team.
|
Resources
powered by:

|
Resources
 |
SLCO1B1 variants linked to statin-induced myopathy Jul 23, 2008 NEW YORK (Reuters Health) - Common variants in the SLCO1B1 gene, which encodes a peptide known to affect hepatic uptake of statins, are strongly tied to an elevated risk of statin-induced myopathy, according to results from a subanalysis of the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). |
 |
Vancomycin underdosing very common in the obese Jul 23, 2008 NEW YORK (Reuters Health) - More than 70% of obese patients do not receive adequate doses of vancomycin, possibly resulting in subtherapeutic concentrations, according to Dallas-based researchers. Criteria that are more stringent suggest that this may also be true of a much wider group of patients. |
 |
Sorafenib slows progression of advanced liver cancer Jul 23, 2008 NEW YORK (Reuters Health) - Treatment of advanced hepatocellular carcinoma with the multiple kinase inhibitor sorafenib improved survival by about 3 months in a multinational, phase III clinical trial reported in the New England Journal of Medicine for July 24. |
 |
HIV-1 integrase inhibitor effective for resistant HIV-1 Jul 23, 2008 NEW YORK (Reuters Health) - In combination with an optimized background regimen, the HIV-1 integrase inhibitor raltegravir (Isentress) is an effective treatment for HIV infection with triple-class drug resistance, new research shows. |
 |
HTLV-1 infection tied to reduced risk of gastric cancer Jul 23, 2008 NEW YORK (Reuters Health) - The presence of human T lymphotropic virus type 1 (HTLV-1) infection appears to reduce the likelihood of developing gastric cancer, possibly through a modulating effect on Helicobacter pylori activity, Japanese researchers report in the July 1st issue of the Journal of Infectious Diseases. |
 |
Reduced creatinine clearance and microalbuminuria both predict stroke Jul 23, 2008 NEW YORK (Reuters Health) - Impairment of the glomerular filtration rate (GFR) and the glomerular filtration barrier are independently associated with stroke, according to an analysis of data from the 1999-2004 National Health and Nutrition Examination Surveys (NHANES). |
 |
WellPoint profit beats estimates, shares rise Jul 23, 2008 NEW YORK (Reuters) - Health insurer WellPoint Inc Wednesday said profit fell 10 percent, as medical costs ate further into premiums, but its shares rose more than 8 percent as results beat projections, helped by strength in its pharmacy and behavioral health businesses. |
 |
UK doctors to face regular tests of competence Jul 23, 2008 LONDON (Reuters) - Britain's 150,000 doctors will have to show they are fit to practice once every five years in the nation's biggest change to medical regulation for 150 years. |
 |
UK's NICE confirms limited use of drug stents Jul 23, 2008 LONDON (Reuters) - Drug-eluting coronary stents can continue to be used on Britain's state health service but only for certain high-risk patients, the country's health cost-effectiveness watchdog said. |
 |
Pulmonary arterial hypertension more severe in carriers of BMPR2 mutation Jul 23, 2008 NEW YORK (Reuters Health) - Among patients with pulmonary arterial hypertension (PAH), those with germline mutations in the gene encoding bone morphogenetic protein receptor 2 (BMPR2) present at an earlier age and with more severe hemodynamic compromise, according to findings from a French study. |
 |
Pulsed, medium-dose UV-A1 phototherapy may be optimal for scleroderma Jul 23, 2008 NEW YORK (Reuters Health) - The benefits of high-dose ultraviolet A1 irradiation for treatment of sclerotic skin disease are attenuated by dose-dependent skin darkening, new research shows. Reducing the dose and frequency of exposures may lead to better clearance of fibrotic skin lesions. |
 |
Race not a determinant of outcome at one year after PCI Jul 23, 2008 NEW YORK (Reuters Health) - African-American patients and Caucasian patients have similar 1-year outcome after percutaneous coronary intervention (PCI), but chronic kidney disease (CKD) has a significant adverse effect on mortality, investigators report. |
 |
Brain tumors diagnosed in first year of life linked to later complications Jul 23, 2008 NEW YORK (Reuters Health) - Long-term survivors of brain tumors diagnosed in the first year of life have a substantial risk of neurological and cognitive complications, according to findings published in the July issue of the Archives of Disease in Childhood. These patients are also at risk of social isolation and decreased health-related quality of life. |
 |
Psychological factors do not affect inflammation Jul 23, 2008 NEW YORK (Reuters Health) - While psychological factors predict incident coronary heart disease (CHD), they do not affect inflammation, according to findings published in the July issue of Arteriosclerosis, Thrombosis, and Vascular Biology. |
 |
U.S. government to release revised U.S. HIV estimates Jul 23, 2008 WASHINGTON (Reuters) - The U.S. Centers for Disease Control and Prevention said on Tuesday it will soon release long-awaited revised estimates of how many Americans become infected with the AIDS virus every year. |
 |
Drug misuse partially accounts for excess mortality in Scotland Jul 23, 2008 NEW YORK (Reuters Health) - Mortality rates in Scotland are substantially higher than in England and Wales - the so-called "Scottish effect." New research suggests that loss of life related to problem drug use accounts for a significant portion of the excess death rate. |
 |
Everolimus improves survival with advanced renal cancer Jul 23, 2008 NEW YORK (Reuters Health) - Treatment with everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can significantly improve progression-free survival in patients with advanced renal cell carcinoma that has not responded to other targeted therapies, according to a report in the July 23rd online issue of The Lancet. |
 |
Ofatumumab promising in refractory follicular lymphoma Jul 22, 2008 NEW YORK (Reuters Health) - The human monoclonal antibody ofatumumab was well tolerated by patients with relapsed or refractory follicular non-Hodgkin's lymphoma in a Phase 1 / 2 safety and efficacy trial, according to European researchers. |
|
 |
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
|  |
|
|
|